Concepedia

IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients

Ana Márquez, Cristina Lucía Dávila-Fajardo, Gema Robledo, José Luís Callejas Rubio, Enrique de Ramón Garrido, Francisco José García Hernández, Rocío González-León, Raquel Ríos-Fernández, J Cabeza Barrera, Ma. Francisca González-Escribano,

Molecular Biology Reports · 2013 · 14 citations · 36 references

DOI

Concepts

References

36

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Stanley Cohen, Paul Emery, Maria Greenwald et al. · Arthritis & Rheumatism · 2006 · 1.6K citations

, , +16

A Genome-Wide Association Study of Psoriasis and Psoriatic Arthritis Identifies New Disease Loci

Ying Liu, Cynthia Helms, Wilson Liao et al. · PLoS Genetics · 2008 · 664 citations · Full text

, , +15

Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.

Michael A. Caligiuri, Antanina Zmuidzinas, Thomas Manley et al. · The Journal of Experimental Medicine · 1990 · 432 citations · Full text

, , +17

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

J.E. Gottenberg · Annals of the Rheumatic Diseases · 2004 · 399 citations · Full text

, , +17

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism

Evdoxia Hatjiharissi, Lian Xu, Daniel Santos et al. · Blood · 2007 · 266 citations · Full text

, , +17